Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer.
In all, 26 patients with advanced GI tract cancer (among whom 23 had liver metastases) were treated in a phase II trial with a 24-h infusion of high-dose ifosfamide and mesna (5 g/m2). Two PR, 1 CR and 4 NC were evidenced among 23 patients evaluable for response. The toxicity was significant and mainly expressed in the hair, digestive tract, granulocytes and CNS. One patient died from CNS and kidney toxicities. Only patients with good clinical indices, normal serum albumin and creatinine levels and without pelvic involvement seemed to be candidates to benefit from the treatment.
Focan
C
C
Clinique Saint-Joseph-Sainte-Elisabeth, Liège, Belgium.
Boossy
J
J
Focan-Henrard
D
D
Reginster
M
M
Claessens
J J
JJ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage*; D008875:Middle Aged
D008623:Mercaptoethanol; D015080:Mesna; D007069:Ifosfamide